Novo Nordisk Pharmaceuticals, Inc., Princeton, N.J., is being awarded a $73,031,525 indefinite delivery type contract for recombinant DNA. Work will be performed in Clayton, N.C. and is expected to be completed by Oct. 31, 2001. Funds will not expire at the end of the fiscal year. The Defense Supply Center Philadelphia, Philadelphia, Pa., is the contracting activity (SP0200-00-D-0511).